Vor Biopharma Inc. (Nasdaq: VOR) has priced an underwritten public offering of 10,000,000 shares of its common stock at $10.00 per share, expecting to raise $100 million. The offering is set to close on November 12, 2025. Vor Bio has also granted underwriters a 30-day option to purchase an additional 1,500,000 shares. J.P. Morgan, Jefferies, Citigroup, and TD Cowen are acting as joint book-running managers for the offering. The offering is made pursuant to a shelf registration statement filed with the SEC. Vor Bio is focused on advancing telitacicept, a dual-target fusion protein, to address autoimmune diseases.

For more information, visit the SEC’s website. This press release does not constitute an offer to sell securities. Vor Bio disclaims any obligation to update forward-looking statements, which involve risks and uncertainties. Media & Investor Contacts: Carl Mauch ([email protected]) and Sarah Spencer ([email protected]).

Read more at GlobeNewswire: Vor Bio Announces Pricing of Public Offering of $100